Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs

M. Odette Gore, Darren K. McGuire

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Type 2 diabetes mellitus is a major and increasingly prevalent independent risk factor for cardiovascular morbidity and mortality worldwide. Glycemic control is a target of therapy and a principal marker of therapeutic success in diabetes, but whether lowering glucose is accompanied by a commensurate reduction in cardiovascular risk is a matter of ongoing controversy. It has become increasingly apparent from recent large-scale clinical outcome trials that glucose lowering is a poor predictor of cardiovascular outcome, and several instances of unexpectedly increased cardiovascular risk with antihyperglycemic drugs have sounded the alarm with regulatory agencies. This article reviews the critical facts that have led to a recent shift in the regulation of glucose-lowering drugs and makes the case for why new and existing antidiabetic medications should be assessed in clinical trials of cardiovascular outcome.

Original languageEnglish (US)
Pages (from-to)258-263
Number of pages6
JournalCurrent Cardiology Reports
Issue number4
StatePublished - 2009

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs'. Together they form a unique fingerprint.

Cite this